Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,661 USD | -4,20% | -13,49% | -11,04% |
Vakgebied
Aantal werknemers: 55
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Difelikefalin-based Product
100,0
%
| 42 | 100,0 % | 21 | 100,0 % | -49,92% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 42 | 100,0 % | 21 | 100,0 % | -49,92% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 54 | 06-08-18 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 12-09-22 |
Scott Terrillion
CMP | Compliance Officer | 61 | 01-11-16 |
Iris Francesconi
IRC | Investor Relations Contact | - | - |
Beth Weinberg
LAW | General Counsel | - | - |
Richard Makara
AUD | Comptroller/Controller/Auditor | 54 | 01-10-14 |
Eric J. Vandal
PRN | Corporate Officer/Principal | - | 02-06-14 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 01-07-10 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 16-07-14 |
Helen Boudreau
BRD | Director/Board Member | 58 | 02-08-23 |
Chief Executive Officer | 54 | 06-08-18 | |
Susan Shiff
BRD | Director/Board Member | 63 | 26-06-20 |
Lisa von Moltke
BRD | Director/Board Member | 65 | 01-11-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 54 656 413 | 46 686 024 ( 85,42 %) | 0 | 85,42 % |
Bedrijfsgegevens
CARA Therapeutics, Inc.
400 Atlantic Street Suite 500
06901, Stamford
+203 406 3700
http://www.caratherapeutics.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-11,04% | 37,72 mln. | |
-5,99% | 84,46 mld. | |
+2,76% | 40,85 mld. | |
-24,88% | 27,69 mld. | |
+53,61% | 24,28 mld. | |
-8,08% | 17,09 mld. | |
-33,74% | 13,67 mld. | |
-16,63% | 11,86 mld. | |
-11,19% | 11,79 mld. | |
-2,25% | 8,07 mld. |
- Beurs
- Aandelen
- Koers CARA
- Onderneming Cara Therapeutics, Inc.